Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 3

Effects of short-term (7 days) empagliflozin administration on body weight gain (A), food intake (B) and water intake(C) of db/db mice. Abbreviations used are the same as in Figure 2. *p < 0.05, †p < 0.01 vs control db/db mice. Values are mean ± SEM (n = 10-11).

Back to article page